Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles.

Xu C, Rao YS, Xu B, Hoffmann E, Jones J, Sellers EM, Tyndale RF.

Biochem Biophys Res Commun. 2002 Jan 11;290(1):318-24.

PMID:
11779172
2.

Nicotine metabolism and CYP2A6 allele frequencies in Koreans.

Kwon JT, Nakajima M, Chai S, Yom YK, Kim HK, Yamazaki H, Sohn DR, Yamamoto T, Kuroiwa Y, Yokoi T.

Pharmacogenetics. 2001 Jun;11(4):317-23.

PMID:
11434509
3.

Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.

Fukami T, Nakajima M, Higashi E, Yamanaka H, Sakai H, McLeod HL, Yokoi T.

Drug Metab Dispos. 2005 Aug;33(8):1202-10. Epub 2005 May 17.

4.

A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.

Fukami T, Nakajima M, Yoshida R, Tsuchiya Y, Fujiki Y, Katoh M, McLeod HL, Yokoi T.

Clin Pharmacol Ther. 2004 Dec;76(6):519-27.

PMID:
15592323
5.
6.

Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method.

Paschke T, Riefler M, Schuler-Metz A, Wolz L, Scherer G, McBride CM, Bepler G.

Toxicology. 2001 Nov 30;168(3):259-68.

PMID:
11684323
7.

Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.

Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers EM, Tyndale RF.

Mol Pharmacol. 2000 Oct;58(4):747-55.

8.

Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.

Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R, Kwon JT, McLeod HL, Yokoi T.

Clin Pharmacol Ther. 2006 Sep;80(3):282-97.

PMID:
16952495
9.

CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.

Malaiyandi V, Goodz SD, Sellers EM, Tyndale RF.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1812-9.

10.

In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais.

Peamkrasatam S, Sriwatanakul K, Kiyotani K, Fujieda M, Yamazaki H, Kamataki T, Yoovathaworn K.

Drug Metab Pharmacokinet. 2006 Dec;21(6):475-84.

11.

CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele.

Fukami T, Nakajima M, Sakai H, McLeod HL, Yokoi T.

Pharmacogenomics J. 2006 Nov-Dec;6(6):401-12. Epub 2006 Apr 25.

PMID:
16636685
12.

Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method.

Mwenifumbo JC, Myers MG, Wall TL, Lin SK, Sellers EM, Tyndale RF.

Pharmacogenet Genomics. 2005 Mar;15(3):189-92.

PMID:
15861044
13.

Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.

Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H, Yamazaki H, Yamamoto T, Kuroiwa Y, Yokoi T.

Clin Pharmacol Ther. 2001 Jan;69(1):72-8.

PMID:
11180041
14.

Determination of coumarin metabolism in Turkish population.

Cok I, Aygün Kocabaş N, Cholerton S, Karakaya AE, Sardaş S.

Hum Exp Toxicol. 2001 Apr;20(4):179-84.

PMID:
11393269
15.

Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity.

Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M.

Biochem Biophys Res Commun. 2001 Jun 8;284(2):455-60.

PMID:
11394901
16.

Functional variants at CYP2A6: new genotyping methods, population genetics, and relevance to studies of tobacco dependence.

Zabetian CP, Gelernter J, Cubells JF.

Am J Med Genet. 2000 Oct 9;96(5):638-45.

PMID:
11054771
17.

Three haplotypes associated with CYP2A6 phenotypes in Caucasians.

Haberl M, Anwald B, Klein K, Weil R, Fuss C, Gepdiremen A, Zanger UM, Meyer UA, Wojnowski L.

Pharmacogenet Genomics. 2005 Sep;15(9):609-24.

PMID:
16041240
18.

Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C.

Ariyoshi N, Takahashi Y, Miyamoto M, Umetsu Y, Daigo S, Tateishi T, Kobayashi S, Mizorogi Y, Loriot MA, Stücker I, Beaune P, Kinoshita M, Kamataki T.

Pharmacogenetics. 2000 Nov;10(8):687-93.

PMID:
11186131
19.

A novel single nucleotide polymorphism altering stability and activity of CYP2a6.

Ariyoshi N, Sawamura Y, Kamataki T.

Biochem Biophys Res Commun. 2001 Mar 2;281(3):810-4.

PMID:
11237731
20.

Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies.

Nowak MP, Sellers EM, Tyndale RF.

Clin Pharmacol Ther. 1998 Oct;64(4):378-83.

PMID:
9797794
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk